Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background Numerous observational studies support the safety and effectiveness of the
direct oral anticoagulants (DOAC) for stroke prevention in atrial fibrillation (AF), but these …

Background Limited real-world data are available regarding the outcome of patients treated
with inappropriate dose of nonvitamin-K antagonist oral anticoagulants (NOACs). Objective …

Background: Direct oral anticoagulants (DOACs) have widely replaced warfarin for stroke
prevention in nonvalvular atrial fibrillation. Our objective was to compare the safety and …

Aim: To analyse the effectiveness and safety of DOAC (direct oral anticoagulants) in non-
valvular atrial fibrillation (NVAF) patients attending clinical practice. Methods: Retrospective …

Background: There are limited data for non-vitamin K antagonist oral anticoagulants
(NOACs) impact on outcomes for patients with atrial fibrillation (AF) and valvular heart …

Introduction and objectives To compare the long-term results of direct oral anticoagulants
(DOAC) vs vitamin K antagonists (VKA) in real-world-patients with nonvalvular atrial …

Objectives This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs.
warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories …

This study aims to provide real-world data about starting-dose of NOACs and dose-
adjustment in patients with atrial fibrillation (AF). In fact, even if new oral anticoagulation …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …